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Abstract
Calciphylaxis is a rare but serious complication in patients with end-stage renal failure. The condition
is associated with high morbidity and mortality. The exact pathogenesis of calciphylaxis and the
optimal treatment are still not known. A disturbance of coagulation seems to be relevant in the
pathogenesis, and anticoagulation therapy seems to be a rational therapy. Reported herein is a
case of calciphylaxis developed in a renal failure patient receiving peritoneal dialysis who was
successfully treated with intravenous unfractionated heparin.
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INTRODUCTION
Although uncommon, calciphylaxis is a serious
complication in patients with end-stage renal failure
(ESRF) (1,2). It is characterized by progressive ischemic
skin necrosis associated with calcification of arterioles
and small dermo-hypodermic arteries (3). The exact
pathogenesis of calciphylaxis is still not well understood,
and most cases are associated with chronic renal failure,
usually with secondary or tertiary hyperparathyroidism
(4). Controversies exist in the optimal treatment of the
condition, and the role of parathyroidectomy in treat-
ing established calciphylaxis (5-10). Anecdotally
low-molecular-weight heparin (LMWH) has been
demonstrated to be useful (2,11). Herein, we report a
case of calciphylaxis developed in a patient with renal
failure who had received peritoneal dialysis for 1 month,
and was treated successfully with intravenous un-
fractionated heparin.
CASE REPORT
A 67-year-old Chinese man (body mass index, 25.1 kg/m2)
presented with ESRF secondary to diabetic nephro-
pathy. He was diagnosed with diabetes mellitus and
hypertension during a routine checkup in 1992.
Significant proteinuria and renal impairment were
noticed in 1997 by his family physician, and he was then
referred to the Renal Unit of the Queen Elizabeth Hospital
for further management. At that time, his 24-hour urine
protein was approximately 3 g/d with a creatinine clearance
of 45 mL/min and serum creatinine concentration of
180 µM. He was also found to have proliferative diabetic
retinopathy requiring laser therapy. He had coronary
artery bypass surgery and mechanical mitral valvular
replacement in 1998 for ischemic heart disease and
functional mitral regurgitation secondary to ischemic
cardiomyopathy, and had been receiving warfarin therapy
since then. His renal function continued to deteriorate
progressively. At the same time, he suffered from
repeated attacks of congestive heart failure. His serum
creatinine concentration rose to 499 µM and creatinine
clearance decreased to 6 mL/min in December 1999.
Peritoneal dialysis therapy was commenced in January
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2000. During the perioperative period for Tenckhoff
catheter insertion, warfarin was temporarily withheld and
LMWH was given. Warfarin therapy was recommenced
after the surgery, and the result of his blood international
normalized ratio (INR) was adjusted back to acceptable
range (INR, 2-3) on discharge.
Two weeks after the Tenckhoff catheter insertion, the
patient had an episode of warfarin overdose with
prolonged INR. Mini-dose vitamin K1 was given to
control the excessive oozing from the previous surgical
wound (12). Warfarin was restarted 3 days later when
the INR result returned to acceptable level. Two weeks
later, he developed a red painful tender spot over his
glans penis. The red spot expanded gradually and formed
a well-demarcated ulcer over the glans penis. It had a
smooth and nonundulating irregular edge with yellow-
ish fibrous material adhered to the base. Physical ex-
amination did not reveal any other ulcers over the body.
His blood pressure was continually stable, and all the
peripheral pulses were palpable. He denied having sexual
contact in the past 2 years, and had not received any
calcium-containing compound or vitamin D preparations.
Laboratory values revealed a white blood cell count of
11.3 x 109/L, hemoglobin 10 g/dL, platelet count 553 x
109/L, urea 15.8 mM, creatinine 370 µM, alkaline
phosphatase 273 IU/L, albumin 27 g/L, calcium 2.1 mM,
phosphate 1.28 mM, and parathyroid hormone 39 pM
(normal range, 1.1-5.7 pM). His diabetes was under
satisfactory control with a hemoglobin A1c level of 7%.
Other pertinent investigations, including venereal disease
research laboratory, fluorescent treponemal antibody, and
treponemal pallidum passive particle agglutination test,
were all nonreactive. The antinuclear factor was weakly
positive (1:160), antidouble-stranded DNA was negative,
antineutrophil cytoplasmic antibody C and P were
negative, and anticardiolipin antibodies immunoglobulin
G level was 6.6 GPL U/mL (<10 GPL U/mL). X-rays
showed calcification of radial and ulcer artery of both
hands, and calcification in the internal pudendal artery,
the penile artery, the dorsal penile artery, and arteries to
the bulb of corpus spongiosum (Fig. 1). A biopsy of the
ulcer was offered but declined by the patient. Clinically
he was diagnosed with calciphylaxis.
The penile ulcer was treated with aggressive local wound
dressing and appropriate antibiotic. Low calcium
concentration peritoneal dialysis solution was used
(Baxter Dianeal, Baxter Healthcare Corporation, Illiniois,
US), and aluminum-containing phosphate binder was
added to achieve better serum phosphate control.
However, there was no improvement in the penile ulcer
for the initial 3 weeks, and the ulcer increased in size
progressively. As a rescue therapy, warfarin was
discontinued, and the patient was maintained on
intravenous unfractionated heparin. The dosage of
heparin was adjusted to achieve an activated partial
thromboplastin time 1.5 to 2 times that of baseline. The
penile ulcer improved gradually after the patient was
placed on intravenous unfractionated heparin, and it
healed completely after 8 weeks of therapy. Warfarin
was reintroduced carefully, and no recurrence of skin
ulcer was noticed after 6 months of follow-up. An assay
on protein C and protein S functional activity was
performed, which showed no evidence of functional
deficiency.
DISCUSSION
Herein we report a case of calciphylaxis in a renal failure
patient who presented with penile ulceration that healed
after receiving intravenous unfractionated heparin
therapy. Calciphylaxis is a rare but serious complication
in patients with ESRF (1). It is characterized by pro-
gressive ischemic skin necrosis with a stereotypic and
diagnostic clinical picture associated with calcification
of arterioles and small dermo-hypodermic arteries (3,4).
Typically, the skin lesions presented as areas of painful
molting resembling livido reticularis with superficial
violaceous nodules involving the tip of the toes or fingers,
or areas above the ankles, thighs, or buttocks (1,4).
Persistent palpable pulse distal to the necrosis is one of
the characteristic features (4,16). Ninety percent of
patients have lower extremity involvement (1), and cases
of penile involvement have been reported in the literature
(13-15). Prognosis of the condition is often poor, with
an overall mortality of 60%; patients usually die of sepsis
(4). Prognosis is better for distal-limited lesion compared
with the proximal lesion (1).
Figure 1. Pelvic radiograph showing calcification in the internal
pudendal artery, the penile artery, the dorsal penile artery, and
arteries to the bulb of corpus spongiosum.
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The landmark series of calciphylaxis syndrome in hu-
mans was described by Gipstein et al (5) in 1976. They
reported a syndrome of tissue necrosis and vascular
calcification in 11 patients with chronic renal failure and
presumed secondary hyperparathyroidism. All the
patients had severe hyperphosphatemia, and the tissue
necrosis healed after parathyroidectomy in seven of 10
patients (5). At that time, dysregulation of calcium and
phosphorous control mechanisms and hyperpara-
thyroidism were believed to be the necessary conditions
for the development of calciphylaxis (17,18). However,
cases without significant abnormalities in serum calcium,
phosphate, and parathyroid hormones, and cases that
developed after successful parathyroidectomy were
described afterward (1,4,17,18). Other risk factors such
as significant weight loss, low serum albumin, and
obesity in white women have also recently surfaced as
important factors predictive of the development of
calciphylaxis (11,17).
Because thrombi can be found in calcified arteriole
adjacent to areas of skin necrosis, pre-existing dis-
turbance of coagulation seems to be relevant in the
pathogenesis of the condition (20). Impaired protein C
activity (6,19) and functional protein S deficiency have
been demonstrated in patients with calciphylaxis (3,6,
19). As in the patient reported here, a high prevalence of
patients with calciphylaxis on warfarin therapy has also
been noted (4,11). This may be attributed to the fluc-
tuation of plasma protein C and protein S levels after the
commencement of warfarin therapy (4). However, a clear
causation between coagulation proteins and calciphylaxis
has not been established yet. Although we were not able
to demonstrate functional protein C and S deficiency in
this patient, fluctuation in his blood INR level was
noticed during the perioperative period of Tenckhoff
insertion, and this may trigger the development of
calciphylaxis.
This case of calciphylaxis occurred around 4 weeks after
initiation of peritoneal dialysis. Generally it is believed
that a longer exposure to renal replacement therapy in
patients with end-stage renal disease may increase the
likelihood of developing calciphylaxis by increasing the
exposure time to factors that predispose to calciphylaxis
(24). However, the time period for the onset of symptoms
of calciphylaxis can range from less than 1 month to as
long as 12 years after the onset of end-stage renal disease
with a median of 2.75 years (1,17). A few cases even
presented with symptoms before the onset of ESRF (1).
Long-standing diabetes in this patient causing diabetic
arteriosclerosis may have contributed to the calcification
of the pudendal artery. This may have shortened the
period between the onset of symptoms of calciphylaxis
and the onset of end-stage renal disease.
Initial management of calciphylaxis includes aggress-
ive wound care with debridement of necrotic tissue
and appropriate systemic antibiotic. Control of
hyperphosphatemia and normalization of calcium-
phosphate products by restricting phosphate in the diet
and using phosphate-binding agents are also essential
(9,16). However, calcium-containing phosphate binder
should be avoided and vitamin D supplements should
be used cautiously (20). Emphasis should also be placed
on using peritoneal dialysate solution of low-calcium
concentration. In the past, parathyroidectomy was
considered by many as a crucial therapy for the control
of hyperparathyroidism, and previous reports showed
better patient survival after parathyroidectomy (5,7,
9,21). However, recent reports have shown that the
improvement in calciphylaxis after parathyroidectomy
is not as dramatic and encouraging as it was initially
thought (6,8,10). The benefit of parathyroidectomy
remains to be controversial, especially for those patients
with mildly elevated or normal serum parathyroid
hormone level (20).
Because thrombosis of the arteriole is a distinctive risk,
the use of anticoagulants seems to be a rationale approach
(11,20). Fluctuation in plasma protein C and protein S
levels need to be avoided. Substitution of LMWH
(enoxaparin 1 mg/kg; Rhone-Poulenc, France) for
warfarin has resulted in healing of lesions in one patient,
and arresting the progressive lesions in another patient
(11). A remarkable response to treatment with LMWH
(Fraxiparine 15 000 Axa/day; Sanofi, France) has also
been reported in a patient with demonstrable functional
protein S deficiency (2). Hence, LMWH may be a useful
form of treatment, especially for patients with relatively
normal parathyroid hormone or phosphate level (2).
However, the use of LMWH for prosthetic heart valve
has not been well documented. Treatment failures
resulting in thrombosed heart valves with stormy clinical
presentations have been reported in patients on LMWH
(22). The penile ulcer of our patient deteriorated despite
aggressive wound treatment, use of low-calcium con-
centration dialysate solution, and aggressive phosphate
control. As a life-saving measure, withholding warfarin
and commencing unfractionated heparin therapy was the
only therapeutic option remaining. Remarkably, this
resulted in dramatic improvement and later complete
healing of the penile ulceration. According to our
knowledge, this is the first case report demonstrating the
successful use of conventional unfractionated heparin
in the treatment of calciphylaxis.
Although heparin therapy may be helpful in the treatment
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of calciphylaxis, recently there was a report of a dialysis
patient presenting with skin ulceration resembling
calciphylaxis induced by heparin and protein S deficiency
(23). The combined presence of heparin-dependent
platelet activating antibodies and functional S deficiency
was identified in the patient. The authors suggest that it
is important to perform skin biopsy and testing for a
hypercoagulable state in patients with end-stage renal
disease and skin ulceration to differentiate between
calciphylaxis and heparin-induced necrosis, which is
important because heparin will be contraindicated in this
condition and distinct treatment options exist for both
conditions.
CONCLUSION
In summary, calciphylaxis is still a condition associated
with high morbidity and mortality, of which the patho-
genic mechanism is still not well understood. Control of
serum calcium, phosphate, and parathyroid hormone
levels is essential for its management, and anti-
coagulation is a rational approach. Both conventional
unfractionated heparin and LMWH might have the
benefit of avoiding fluctuation in plasma protein C and
protein S levels, and this may result in the improvement
of skin ulceration and better patient survival. It is still
important to look for other causes of skin ulceration in
patients with end-stage renal disease that require a
distinct form of treatment in which heparin therapy may
be contraindicated.
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